What's Going On With Cassava Sciences Today?

Comments
Loading...
Zinger Key Points
  • Cassava Sciences' upcoming conference call on August 8 and plans to extend simufilam trials.
  • The passing of long-time board member Sanford "Sandy" Robertson and his contributions to the company.

Cassava Sciences, Inc. SAVA shares are trading higher Monday. Here’s what you need to know.

What To Know: Cassava Sciences is scheduled to hold a conference call on Thursday, August 8 2024, to discuss recent developments and provide a company update. Analysts expect the company to report an earnings per share (EPS) loss of 40 cents.

Additionally last week, Cassava announced plans to extend its open-label extension trials for simufilam by up to 36 months, allowing patients from previous trials to continue their treatment while awaiting Phase 3 trial results.

In Memoriam: Cassava Sciences also mourns the loss of long-time board member Sanford “Sandy” Robertson, who served on the Board of Directors since the company’s inception as a public entity in 1998.

SAVA Price Action: Cassava Sciences shares were up by 20.9% at $35.20, according to Benzinga Pro.

See Also:

Photo by solarseven on Shutterstock.

Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!